Jonsson Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.cancer.ucla.edu

Clinical Trials

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Phase 1

Suspended

Conditions: Borderline Resectable Pancreatic Adenocarcinoma
Locally Advanced Pancreatic Ductal Adenocarcinoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Core Biopsy
Drug: Fluorouracil
Drug: Irinotecan
Drug: Leucovorin
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Drug: Quemliclustat
Drug: Zimberelimab

First Posted Date: 2023-01-18

Last Posted Date: 2024-02-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 56

Registration Number: NCT05688215

Locations: 🇺🇸
Yonemoto,Lisa, Los Angeles, California, United States

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

Phase 2

Recruiting

Conditions: Anatomic Stage I Breast Cancer AJCC V8
Anatomic Stage II Breast Cancer AJCC V8
Anatomic Stage III Breast Cancer AJCC V8

Interventions: Procedure: Biospecimen Collection
Drug: Placebo Administration
Drug: Fisetin
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2022-10-27

Last Posted Date: 2024-12-19

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 88

Registration Number: NCT05595499

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
UCLA Health Cancer Care in Alhambra, Alhambra, California, United States
🇺🇸
UCLA Health Beverly Hills Primary & Specialty Care, Beverly Hills, California, United States

and more 4 locations

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Phase 1

Recruiting

Conditions: Lung Adenocarcinoma

Interventions: Drug: Alpha-methyl-4-deoxy-4-[(18)F]fluoro-D-glucopyranoside
Procedure: Computed Tomography
Other: Laboratory Biomarker Analysis
Procedure: Positron Emission Tomography

First Posted Date: 2022-09-28

Last Posted Date: 2024-02-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 60

Registration Number: NCT05558904

Locations: 🇺🇸
Yesenia Calzada, Los Angeles, California, United States

Value-based Integrated Recommendation Software Guiding Ovarian Cancer Treatment (VIRGO2)

Not Applicable

Recruiting

Conditions: Ovarian Cancer

Interventions: Other: Mobile Application

First Posted Date: 2022-08-31

Last Posted Date: 2024-01-22

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 200

Registration Number: NCT05523700

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

Phase 2

Active, not recruiting

Conditions: Oligometastatic Prostate Carcinoma
Prostate Adenocarcinoma
Recurrent Prostate Adenocarcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Other: Quality-of-Life Assessment
Drug: Lutetium Lu-177 PNT2002
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2022-08-11

Last Posted Date: 2024-10-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 93

Registration Number: NCT05496959

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Phase 1

Not yet recruiting

Conditions: Diffuse Hemispheric Glioma, H3 G34-Mutant

Interventions: Biological: Ipilimumab
Biological: Nivolumab
Biological: Dendritic Cell Tumor Peptide Vaccine
Procedure: Leukapheresis
Drug: Placebo Administration
Drug: Poly ICLC
Procedure: Resection

First Posted Date: 2022-07-14

Last Posted Date: 2024-06-04

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 15

Registration Number: NCT05457959

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

Phase 1

Recruiting

Conditions: Stage IVA Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma
Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Castration-Resistant Prostate Carcinoma
Stage IVB Prostate Cancer AJCC v8

Interventions: Procedure: Image Guided Biopsy

First Posted Date: 2022-05-31

Last Posted Date: 2024-04-30

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT05398302

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1

Recruiting

Conditions: Metastatic HER2-Positive Breast Carcinoma
Prognostic Stage IB Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Prognostic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8

Interventions: Other: Quality-of-Life Assessment
Drug: Fulvestrant
Drug: Carboplatin
Drug: Ribociclib
Drug: Docetaxel
Biological: Trastuzumab
Biological: Pertuzumab
Drug: Tucatinib

First Posted Date: 2022-04-08

Last Posted Date: 2024-04-18

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT05319873

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma
High-grade B-cell Lymphoma
Transformed Lymphoma
Secondary Central Nervous System Lymphoma

Interventions: Drug: Acalabrutinib

First Posted Date: 2022-02-25

Last Posted Date: 2024-11-05

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT05256641

Locations: 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

Early Phase 1

Recruiting

Conditions: Prostate Carcinoma

Interventions: Procedure: Biopsy of Prostate
Other: Gallium Ga 68 Gozetotide
Procedure: Transrectal Ultrasonography Guided Biopsy

First Posted Date: 2021-12-16

Last Posted Date: 2024-02-13

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT05160597

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy